The White House reported on Aug. 17 that prescription drug prices in the United States have recorded their steepest annual decline since 1963, a 3.9% drop since President Trump took office and a month‑over‑month decrease throughout 2026.
The decline stems from the administration’s Most Favored Nation (MFN) pricing rule, which obliges 17 of the world’s largest drugmakers—representing about 86% of the branded market—to match U.S. prices to the lowest rates paid in comparable developed nations. The new TrumpRx platform has already generated roughly $700 million in savings, and high‑cost products such as GLP‑1 diabetes drugs have fallen from over $1,000 a month to as low as $149. Fertility treatments, inhalers, insulin, and cholesterol medicines have seen cuts ranging from 50% to 90%.
The Department of Veterans Affairs reported more than $10 billion in pharmaceutical savings this fiscal year, and officials project hundreds of billions in long‑term savings as the MFN framework expands. No prior administration has achieved a comparable reduction, and the administration says the trend will continue to lower costs for American families.
